HeartBeam announced a strategic collaboration with the Icahn School of Medicine at Mount Sinai to accelerate the joint development and validation of next-generation AI-ECG algorithms. The partnership combines HeartBeam's patented ECG platform, which captures the heart's electrical activity from three non-coplanar dimensions, with Mount Sinai's clinically annotated 12-lead ECG datasets and artificial intelligence expertise to advance AI-driven cardiac monitoring.
By leveraging longitudinal, high-fidelity synthesized 12-lead ECG data collected from patients in home settings alongside Mount Sinai's clinical data resources, the collaboration aims to accelerate the training and validation of AI models designed to support personalized cardiac insights. This initiative seeks to expand potential clinical indications and enable broader applications in preventive cardiology, chronic disease management and remote patient monitoring. The HeartBeam System with 12-Lead ECG synthesis software for arrhythmia assessment received FDA clearance in December 2025, with details on the intended use of its technology available at https://www.heartbeam.com/indications.
The collaboration represents a significant step toward transforming cardiac care delivery by potentially enabling physicians to identify cardiac health trends and acute conditions outside traditional medical facilities. HeartBeam's technology platform is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence, which could redefine the future of cardiac health management. The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the company holds over 20 issued patents related to technology enablement.
This partnership matters because it addresses critical gaps in current cardiac monitoring approaches by combining innovative 3D ECG capture with artificial intelligence and extensive clinical validation. The implications extend beyond immediate clinical applications to potentially reshape how cardiac conditions are detected and managed in everyday settings, making specialized cardiac insights more accessible to patients regardless of location. The latest news and updates relating to HeartBeam are available in the company's newsroom at https://ibn.fm/BEAT.
